论文部分内容阅读
为了解前列腺癌临床流行病学情况，对上海市市区前列腺癌新发病例进行全人群对照研究。２３８例前列腺癌年龄构成为：５０岁～１１例（４．６％），６０岁～６４例（２６．９％），７０岁～１１５例（４８．３％），８０岁～４５例（１８．９％），９０～９３岁３例（１．３％）。肛指检查阳性率６５．５％，合并良性前列腺增生症占５６．３％。临床分期Ｔ１１２例（５．４％），Ｔ２８８例（３９．８％），Ｔ３８４例（３８．０％），Ｔ４３７例（１６．８％）。９０例（３７．８％）确定有远处转移。２２０例（９２．４％）细胞类型为腺癌。１８４例患者病理分级１级２３例（１２．５％），２级７３例（３９．７％），３级８８例（４７．８％）。临床分期与肿瘤远处转移率有关（Ｐ＜０．００１）。平均血清ＰＳＡ为８７．３μｇ／Ｌ，与人群对照组及ＢＰＨ对照组有显著性差异（Ｐ＜０．００１）。对血清ＰＳＡ的价值，前列腺癌的治疗方法进行了初步探讨。
To understand the clinical epidemiology of prostate cancer, a population-based comparative study of newly diagnosed prostate cancer patients in Shanghai was conducted. The age of 238 cases of prostate cancer consisted of 50 to 11 cases (4.6%), 60 to 64 cases (26.9%), 70 to 115 cases (48.3%) and 80 to 45 cases 18.9%), 3 cases (1.3%) 90-93 years old. Anal check positive rate of 65.5%, combined benign prostatic hyperplasia accounted for 56.3%. The clinical stage of T112 cases (5.4%), T288 cases (39.8%), T384 cases (38.0%), T437 cases (16.8%). 90 cases (37.8%) identified distant metastasis. 220 cases (92.4%) of the cell types of adenocarcinoma. The pathological grade of the 184 patients was 23 (12.5%) of grade 1, 73 of grade 2 (39.7%) and 88 of grade 3 (47.8%). The clinical stage was related to distant metastasis of tumor (P <0.001). The mean serum PSA was 87.3 μg / L, which was significantly different from the control group and BPH control group (P <0.001). The value of serum PSA, prostate cancer treatment methods were initially explored.